Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Profound Medical Corp. - common stock (NQ:PROF)

6.465 -0.025 (-0.39%)
Streaming Delayed Price Updated: 9:57 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,657
Open 6.480
Bid (Size) 6.300 (100)
Ask (Size) 6.630 (200)
Prev. Close 6.490
Today's Range 6.270 - 6.725
52wk Range 3.760 - 8.950
Shares Outstanding 20,208,948
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions 
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Announces Upcoming Investor Events
From Profound Medical Corp.
Via GlobeNewswire

Performance

YTD
-15.6%
-15.6%
1 Month
-23.4%
-23.4%
3 Month
+7.9%
+7.9%
6 Month
+14.8%
+14.8%
1 Year
+10.5%
+10.5%

More News

Read More
News headline image
Earnings Scheduled For November 13, 2025 ↗
Via Benzinga
News headline image
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
From Profound Medical Corp.
Via GlobeNewswire
InvestorNewsBreaks – Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) Closes $36 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Profound Medical Corp. Announces Closing of Private Placement
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Corp. Announces Upsize of Private Placement
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Reports Strong Third Quarter 2025 Financial Results
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Participate in the Stifel 2025 Healthcare Conference
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical to Participate in Lake Street’s 9th Annual Best Ideas Growth Conference
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment
From Profound Medical Corp.
Via GlobeNewswire
News headline image
Profound Medical Posts Wider Loss in Q2 ↗
Via The Motley Fool
News headline image
Profound Medical Announces Second Quarter 2025 Financial Results
From Profound Medical Corp.
Via GlobeNewswire

Frequently Asked Questions

Is Profound Medical Corp. - common stock publicly traded?
Yes, Profound Medical Corp. - common stock is publicly traded.
What exchange does Profound Medical Corp. - common stock trade on?
Profound Medical Corp. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Profound Medical Corp. - common stock?
The ticker symbol for Profound Medical Corp. - common stock is PROF on the Nasdaq Stock Market
What is the current price of Profound Medical Corp. - common stock?
The current price of Profound Medical Corp. - common stock is 6.465
When was Profound Medical Corp. - common stock last traded?
The last trade of Profound Medical Corp. - common stock was at 02/09/26 09:57 AM ET
What is the market capitalization of Profound Medical Corp. - common stock?
The market capitalization of Profound Medical Corp. - common stock is 130.65M
How many shares of Profound Medical Corp. - common stock are outstanding?
Profound Medical Corp. - common stock has 131M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.